=> d ibib abs hitstr 1-42 125

L25 ANSWER 1 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:502726 HCAPLUS
DOCUMENT NUMBER: 137:68164
TITLE: Pharmaceutical aerosols containing hydrofluorocarbon propellants and devices for their administration
INVENTOR(S): Goodman, Michael; Lindahl, Ake
PATENT ASSIGNEE(S): Biogland Ireland (R&D) Limited, Ire.
SOURCE: U.S., 8 pp., Cont.-in-part of U.S. Ser. No. 913,226, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6413496	B1	20020702	US 1999-325927	19990604 <--
WO 9824420	A1	19980611	WO 1997-GB3360	19971204 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9710923	A	19980902	ZA 1997-10923	19971204 <--

PRIORITY APPLN. INFO.:
GB 1996-25171 A 19961204 <--
GB 1996-26449 A 19961220 <--
US 1997-913226 B2 19970909 <--
WO 1997-GB3360 A2 19971204 <--

AB A device for providing pharmaceutical doses comprising a container, filled with a pharmaceutical **compn.** including a pharmaceutically active agent in a soln. of liquefied 1,1,1,2-tetrafluoroethane (HFC-134a), or 1,1,1,2,3,3,3 heptafluoropropane (HFC-227) and a carrier. The carrier can be a pharmaceutically acceptable alc., polyol, (poly)alkoxy deriv., fatty acid alkyl ester, polyalkylene glycol, or DMSO. The device includes a valve arranged for delivering aerosol doses of said pharmaceutical **compn.** to the exterior of the container, and at least a portion of the device is formed from a polyester. For example, a **compn.** comprising beclomethasone dipropionate (BDP) with HFC- 134a suitable for use in a device of this invention was formulated from the following ingredients (by wt.): BDP 0.164%, ethanol 96% 4.992%, and HFC-134a. Each expelled dose of the this formulation is approx. 25 .mu.L and provides 50 .mu.g of BDP.

IT **139755-83-2**, Sildenafil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aerosols contg. hydrofluorocarbon propellants and devices for their administration)

RN 139755-83-2 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)

Richard Byrd - Alvin Carter — Wm McGussey
Roy Clark - George Marshall - Lewis Powell

↔ Civil War ↔ Virginia



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 2 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:385005 HCAPLUS
DOCUMENT NUMBER: 136:380107
TITLE: Combination **compositions** and methods using phosphodiesterase inhibitors and other agents for the treatment of anorectal disorders
INVENTOR(S): Parks, Thomas P.; Mak, Vivien; Lee, Jung-Chung; Lee, Charles
PATENT ASSIGNEE(S): Cellergy Pharmaceuticals, Inc., USA
SOURCE: U.S., 29 pp., Cont.-in-part of U.S. Ser. No. 460,306. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6391869	B1	20020521	US 2000-595390	20000614 <--
US 6395736	B1	20020528	US 1999-460306	19991213 <--
US 2002072522	A1	20020613	US 2001-919590	20010730 <--

PRIORITY APPLN. INFO.:
US 1998-112325P P 19981214 <--
US 1999-139916P P 19990617 <--
US 1999-155318P P 19990921 <--
US 1999-460306 A2 19991213 <--
US 2000-595390 A2 20000614 <--
US 2000-222267P P 20000731
US 2001-769621 A2 20010123

AB Compns. and methods for the treatment of anorectal disorders are provided in which certain combinations of NO donors, PDE inhibitors, superoxide scavengers, .beta.-adrenergic agonists, cAMP-dependent protein kinase activators, .alpha.1-adrenergic antagonists, L-type calcium channel blockers, estrogens, ATP-sensitive potassium channel activators and smooth muscle relaxants are used.

IT **139755-83-2**, Sildenafil
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phosphodiesterase inhibitors and other agents for combination treatment of anorectal disorder)

RN 139755-83-2 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 3 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:185616 HCAPLUS
DOCUMENT NUMBER: 136:252482
TITLE: Preparation of aqueous clear solution dosage forms with bile acids
INVENTOR(S): Yoo, Seo Hong
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 35 pp., Cont.-in-part of U. S. 6,251,428.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002031558	A1	20020314	US 2001-778154	20010205 <--
US 6251428	B1	20010626	US 1999-357549	19990720 <--
PRIORITY APPLN. INFO.:			US 1998-94069P P	19980724 <--
			US 1999-357549 A2	19990720 <--
			US 2000-180268P P	20000204 <--

AB Compns. for pharmaceutical and other uses comprise clear aq. solns. of bile acids which do not form any detectable ppts. over selected ranges of pH values of the aq. soln. The compns. comprise (i) water, (ii) a bile acid component in the form of a bile acid, bile acid salt, or a bile acid conjugated with an amine by an amide linkage; and (iii) either or both an aq. sol. starch conversion product and an aq. sol. non-starch polysaccharide. The **compn**. remains in soln. without forming a ppt. over a range of pH values and, according to one embodiment, remains in soln. for all pH values obtainable in an aq. system. The **compn** . may further contain a pharmaceutical compd., such as insulin, heparin, bismuth compds., amantadine and rimantadine. For example, soln. dosage forms that did not show any pptn. at any pH were prepd. contg. ursodeoxycholic acid (UDCA) 22 g, 1N NaOH 75 mL, chenodeoxycholic acid (CDCA) 3 g, maltodextrin 875 g, bismuth citrate 4 g, citric acid or lactic acid as needed, and purified water to make 1 L.

IT **139755-83-2**, Sildenafil **171599-83-0**, Sildenafil citrate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of stable aq. solns. contg. bile acids for therapy)

RN 139755-83-2 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 171599-83-0 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 77-92-9
CMF C6 H8 O7



L25 ANSWER 4 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:72805 HCAPLUS
DOCUMENT NUMBER: 136:139829
TITLE: **Compositions** comprising sibutramine metabolites in combination with phosphodiesterase inhibitors
INVENTOR(S): Jerussi, Thomas P.; Senanayake, Chrisantha H.; Fang, Qun K.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 24 pp., Cont.-in-part of U.S. Ser. No. 662,135.

CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 2002010198	A1	20020124	US 2001-770663	20010129	<--
US 6331571	B1	20011218	US 1999-372158	19990811	<--
US 6339106	B1	20020115	US 2000-662135	20000914	<--
WO 2002060424	A2	20020808	WO 2002-US2040	20020123	

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 1999-372158	A2	19990811	<--
US 2000-662135	A2	20000914	
US 1998-97665P	P	19980824	<--
US 1998-99306P	P	19980902	<--
US 2001-770663	A	20010129	

AB Methods are disclosed for the treatment and prevention of disorders and conditions such as, but are not limited to: eating disorders; wt. gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence. Pharmaceutical compns. and dosage forms are also disclosed which comprise a racemic or optically pure sibutramine metabolite and an optional drug. Sibutramine free base was prepd. by the reaction of chlorbenzylnitrile dibromopropane in the presence of NaH in DMSO, followed by the treatment of the resulting 1-(4-chlorophenyl)cyclobutanecarbonitrile with isobutylmagnesium bromide and finally treatment with HCHO. The fee base was resolved into the (R) and (S) isomers and converted into their metabolites. Hard gelatin capsules contained racemic or optically pure sibutramine metabolite 5.0, microcryst. cellulose 90.0, pregelatinized starch 100.3, croscarmellose sodium 7.0, and Mg stearate 0.2 mg.

IT **139755-83-2**, Sildenafil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. comprising sibutramine metabolites in combination with phosphodiesterase inhibitor)

RN 139755-83-2 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



IT **139755-82-1**, Desmethylsildenafil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(desmethylsildenafil; compns. comprising sibutramine metabolites in combination with phosphodiesterase inhibitor)
RN 139755-82-1 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



L25 ANSWER 5 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:51989 HCAPLUS
DOCUMENT NUMBER: 136:96083
TITLE: Methods of using and **compositions** comprising (+)-sibutramine optionally in combination with other pharmacologically active compounds
INVENTOR(S): Young, James W.; Jerussi, Thomas P.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U. S. Ser. No. 442,263.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002006964	A1	20020117	US 2001-770393	20010129 <--
WO 2002060427	A2	20020808	WO 2002-US2038	20020123

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 1995-442263 A2 19950516 <--
US 2001-770393 A 20010129

AB This invention encompasses methods for the treatment and prevention of disorders that include, but are not limited to, eating disorders; wt. gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence. The invention further encompasses pharmaceutical compns. and dosage forms which comprise optically pure (+)-sibutramine, optionally in combination with a phosphodiesterase inhibitor or a lipase inhibitor.

IT **139755-82-1**, Desmethylsildenafil
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(desmethylsildenafil; therapeutic compns. comprising (+)-sibutramine and optionally in combination with other pharmacol. active compds.)

RN 139755-82-1 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



IT **139755-83-2**, Sildenafil
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic compns. comprising (+)-sibutramine and optionally in combination with other pharmacol. active compds.)

RN 139755-83-2 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



L25 ANSWER 6 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:51988 HCAPLUS
DOCUMENT NUMBER: 136:107551
TITLE: Method of using and **compositions** comprising (-) sibutramine optionally in combination with other pharmacologically active compounds
INVENTOR(S): Young, James W.; Jerussi, Thomas P.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S. Ser. No. 721,669.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 2002006963	A1	20020117	US 2001-770665	20010129	<--
WO 2002060428	A2	20020808	WO 2002-US2039	20020123	

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 1992-903040	B1	19920623 <--
US 1995-461608	B1	19950605 <--
US 2000-721669	A2	20001127
US 2001-770665	A	20010129

AB This invention encompasses methods for the treatment and prevention of disorders that include, but are not limited to, eating disorders; wt. gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence. The invention further encompasses pharmaceutical compns. and dosage forms which comprise optically pure (-) sibutramine, optionally in combination with a phosphodiesterase inhibitor or a lipase inhibitor. A soln. of 21.7 g L-dibenzyltartaric acid ("L-DBTA") in Et acetate was added to a soln. of 12.3 g racemic sibutramine in Et acetate and the reaction mixt. was heated to reflux and cooled to room temp. The white ppt. was collected and the solid was then suspended in Et acetate and heated at reflux for 30 min. The solid was collected and further crystd. in iso-Pr alc. to give 11.3 g of (-)-sibutramine L-DBTA (yield 76%). Free base was obtained by treatment of (-)-sibutramine L-DBTA with satd. aq. NaHCO3 and extd. with chloroform. A pharmacol. study was conducted to det. the relative potency, comparative efficacy, binding affinity, and toxicity of the enantiomers and racemic mixt. of sibutramine. A capsule contained (-) sibutramine 10.0, lactose 70.0, corn starch 19.5, and magnesium stearate 0.05 mg.

IT **139755-82-1**, Desmethylsildenafil **139755-83-2**, Sildenafil
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(method of using and compns. comprising (-) sibutramine optionally in combination with other pharmacol. active compds.)

RN 139755-82-1 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 139755-83-2 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



L25 ANSWER 7 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:489213 HCAPLUS
DOCUMENT NUMBER: 135:82004
TITLE: Hydrogel-driven drug dosage forms comprising water-swellable **compositions**
INVENTOR(S): Appel, Leah Elizabeth; Beyerinck, Ronald Arthur; Chidlaw, Mark Brian; Curatolo, William John; Friesen, Dwayne Thomas; Smith, Kelly Lincoln; Thombre, Avinash Govind
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001047500	A1	20010705	WO 2000-IB1920	20001220 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,

LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002015731	A1	20020207	US 2000-745095	20001220	<--
EP 1242055	A1	20020925	EP 2000-983435	20001220	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
NO 2002002970	A	20020620	NO 2002-2970	20020620	<--
PRIORITY APPLN. INFO.:			US 1999-171968P	P 19991223	<--
			WO 2000-IB1920	W 20001220	

AB A controlled-release dosage form has a coated core with the core comprising a drug-contg. **compn.** and a water-swellable **compn.**, each occupying sep. regions within the core. The drug-contg. **compn.** comprises a low-soly. drug and a drug-entraining agent. The coating around the core is water-permeable, water-insol. and has at least one delivery port therethrough. A variety of formulations having specific drug release profiles are disclosed. Thus, 400m mg of a drug-contg. layer, contg. sildenafil 35, xylitol 30, polyethylene oxide 29, sodium starch glycolate 5, and magnesium stearate 1% was compressed with 100 mg of a water-swellable layer contg. sodium starch glycolate 74.5, microcryst. cellulose 25, and magnesium stearate 0.5% to make a controlled-release bilayer tablet. The amt. of the drug release within 2, 8 and 20 h was 25, 74, and 98%, resp.

IT **171599-83-0**, Sildenafil citrate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrogel-driven drug dosage forms comprising water-swellable compns.)

RN 171599-83-0 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 77-92-9
CMF C6 H8 O7



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 8 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:396644 HCAPLUS
DOCUMENT NUMBER: 135:24671
TITLE: Solid carriers for improved delivery of active ingredients in pharmaceutical **compositions**
INVENTOR(S): Patel, Manesh V.; Chen, Feng-jing
PATENT ASSIGNEE(S): Lipocine, Inc., USA
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2001037808	A1	20010531	WO 2000-US32255	20001122	<--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
US 6248363	B1	20010619	US 1999-447690	19991123	
EP 1233756	A1	20020828	EP 2000-980761	20001122	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					

PRIORITY APPLN. INFO.: US 1999-447690 A 19991123 <--
WO 2000-US32255 W 20001122

AB The present invention provides solid pharmaceutical compns. for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or sep. administered. In one embodiment, the solid pharmaceutical **compn.** includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical **compn.** includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compns. of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritionals, cosmeceuticals and diagnostic agents. A **compn.** contained glyburide 1, PEG 40 stearate 33, glycerol monolaurate 17, and nonpareil seed 80 g.

IT **171599-83-0**, Sildenafil citrate

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

RN 171599-83-0 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 77-92-9
CMF C6 H8 O7



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 9 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:380370 HCAPLUS
DOCUMENT NUMBER: 135:9995
TITLE: Pharmaceuticals containing sildenafil for treating male erectile dysfunction
INVENTOR(S): Vallabhaneni, Ramakrishna Rao
PATENT ASSIGNEE(S): Natco Pharma Ltd., India
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001035926	A2	20010525	WO 2000-IN105	20001024 <--
WO 2001035926	A3	20011227		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1237538 A2 20020911 EP 2000-990872 20001024 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

PRIORITY APPLN. INFO.: IN 1999-MA1128 A 19991118 <--
WO 2000-IN105 W 20001024

AB The invention relates to a novel pharmaceutical **compn.** contg. sildenafil useful for nasal administration in the treatment of male erectile dysfunction due to a variety of causes. The **compn.** is also effective in patients with erectile dysfunction due to spinal cord injury. The pharmaceutical **compn.** is in the form of a soln. or a colloidal dispersion in a vehicle filled into a specially designed dosing device for nasal administration. The invention also provides a method for prepg. the **compn.** contg. sildenafil for nasal application for the treatment of male erectile dysfunction. Thus, a formulation contained sildenafil citrate 10.000, PEG-300 30.000, glycerol 20.000, and HCl 10.000% and water to 1.0 mL.

IT **139755-83-2**, Sildenafil **171599-83-0**, Sildenafil citrate **252920-86-8 252951-59-0 252959-28-7 255885-45-1 255885-46-2 255885-47-3 255885-48-4 255885-49-5 255885-50-8 340963-09-9**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmaceuticals contg. sildenafil for treating male erectile dysfunction)

RN 139755-83-2 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 171599-83-0 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 77-92-9
CMF C6 H8 O7



RN 252920-86-8 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 252951-59-0 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, mononitrate (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 7697-37-2
CMF H N O3



RN 252959-28-7 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 255885-45-1 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, sulfate (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 7664-93-9
CMF H2 O4 S



RN 255885-46-2 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, phosphate (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 7664-38-2
CMF H3 O4 P



RN 255885-47-3 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 255885-48-4 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 255885-49-5 HCAPLUS
CN Butanedioic acid, compd. with 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 110-15-6
CMF C4 H6 O4



RN 255885-50-8 HCAPLUS
CN L-Ascorbic acid, compd. with 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-

pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 50-81-7
CMF C6 H8 O6

Absolute stereochemistry.



RN 340963-09-9 HCAPLUS
CN Propanoic acid, 2-hydroxy-, compd. with 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 50-21-5
CMF C3 H6 O3



L25 ANSWER 10 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:338347 HCAPLUS
DOCUMENT NUMBER: 134:348287
TITLE: **Composition** and method for decreasing neurologic symptomatology comprising phosphodiesterase inhibitor
INVENTOR(S): Swope, David M.
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2001032170	A1	20010510	WO 2000-US40901	20000913	<--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
EP 1218003	A1	20020703	EP 2000-974101	20000913	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL					
US 2002032203	A1	20020314	US 2000-731362	20001205	<--
US 6380267	B1	20020430			
US 2002119978	A1	20020829	US 2002-116840	20020405	

PRIORITY APPLN. INFO.: US 1999-153586P P 19990913 <--
WO 2000-US40901 W 20000913
US 2000-731362 A1 20001205

AB A method of decreasing the signs or symptomatol. in a patient with a neurol. condition or disease, or in a patient due to effects of exposure to an exogenous substance, such as a pharmaceutical agent, comprising selecting a patient having at least one sign or symptom selected from the group consisting of akinesia, bradykinesia, dyskinesias, gait disturbances, posture disturbances, rigid limbs, speech impairments and tremor and administering to the patient one or more than one EDs of a phosphodiesterase inhibitor. A **compn.** for decreasing the signs or symptomatol. in a patient with a neurol. condition or disease, or in a patient due to effects of exposure to an exogenous substance, such as a pharmaceutical agent, the **compn.** comprising an ED of one or more

than one phosphodiesterase inhibitor combined with an ED of one or more than one addnl. pharmaceutical agent known to decrease signs or symptomatol. in a patient with a neurol. condition or disease. A 60 yr old male patient with Parkinson's disease who was taking 700 mg of levodopa/ day was initially treated with 50 mg of sildenafil/day. During the treatment, his dyskinesias were significantly reduced and his dose of sildenafil was decreased to 25 mg and his dose of levodopa was reduced to 300-400 mg/day.

IT **139755-83-2**, Sildenafil
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**compn**. and method for decreasing neurol. symptomatol. comprising phosphodiesterase inhibitor)

RN 139755-83-2 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 11 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:300502 HCAPLUS
DOCUMENT NUMBER: 134:300832
TITLE: Sildenafil preparation for treatment of erectile dysfunction
INVENTOR(S): Laniado, Shlomo; Stern, Naftali; Keren, Gad
PATENT ASSIGNEE(S): Israel
SOURCE: PCT Int. Appl., 5 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001028541	A2	20010426	WO 2000-IL622	20001005 <--
WO 2001028541	A3	20020314		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,

CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: IL 1999-132460 A 19991019 <--
AB The present invention relates to a synergistic **compn.** for the treatment of erectile dysfunction comprising suitable amts. of Sildenafil and of L-arginine or of pharmaceutically acceptable salts thereof. The **compn.** comprises preferably 25-100 mg of Sildenafil and 0.5-1.5 g of L-arginine. The **compn.** may comprise suitable excipients and advantageously in oral dosage form for the treatment of erectile dysfunction.
IT **139755-83-2**, Sildenafil
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synergistic **compn.** contg. Sildenafil and arginine for treatment of erectile dysfunction)
RN 139755-83-2 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



L25 ANSWER 12 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:283767 HCAPLUS
DOCUMENT NUMBER: 134:285617
TITLE: Tablets with a gellan gum coating
INVENTOR(S): Flanagan, John; Smith, Terry L.; Barkley, Aaron; Nicholson, Richard E.; Callahan, Timothy P.
PATENT ASSIGNEE(S): Monsanto Company, USA
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001026634	A1	20010419	WO 2000-US28032	20001011 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1220660	A1	20020710	EP 2000-970753	20001011 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

PRIORITY APPLN. INFO.: US 1999-416181 A1 19991011 <--
WO 2000-US28032 W 20001011

AB A tablet coating useful for coating an active selected from the group consisting of aspirin, ibuprofen, naproxen sodium, acetaminophen, celecoxib, sildenafil citrate, alendronate sodium, an analgesic in combination with one or more of an antitussive, antihistamine, decongestant and expectorant, oxaprozin, comprising gellan gum along with a process which comprises admixing gellan gum and water under effective shear conditions to prep. an aq. gellan gum coating **compn.** thereof whereby the aq. gellan gum coating **compn.** is applied in an adherent fashion to a placebo or a tablet contg. an active to form a gellan gum coated placebo or gellan gum coated active.

IT **171599-83-0**, Sildenafil citrate
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(tablets with a gellan gum coating)

RN 171599-83-0 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 77-92-9
CMF C6 H8 O7



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 13 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:114953 HCAPLUS
DOCUMENT NUMBER: 134:157562

TITLE: Methods and pharmaceutical **compositions** for increasing optic nerve, choroidal and retinal blood flow by cyclic-GMP analogs, cyclic-GMP phosphodiesterase inhibitors, or guanylate cyclase activators.
INVENTOR(S): Sponsel, William E.
PATENT ASSIGNEE(S): Board of Regents, the University of Texas System, USA
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001010406	A2	20010215	WO 2000-US21929	20000810 <--
WO 2001010406	A3	20020808		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1246605	A2	20021009	EP 2000-952721	20000810 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

PRIORITY APPLN. INFO.: US 1999-148150P P 19990810 <--
WO 2000-US21929 W 20000810

AB A method is provided for improving visual function and maximizing the health of the optic nerve and retina by increasing blood flow velocity therein through the application of an effective amt. of a formulation of an agent that is a cyclic-GMP analog, a cyclic-GMP phosphodiesterase inhibitor, or a guanylate cyclase activator. Compds. of the invention include e.g. sildenafil citrate (Viagra).

IT **139755-83-2**, Sildenafil **171599-83-0**, Sildenafil citrate
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclic-GMP analog, cyclic-GMP phosphodiesterase inhibitor, or guanylate cyclase activator for increasing optic nerve, choroidal and retinal blood flow.)

RN 139755-83-2 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 171599-83-0 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 77-92-9
CMF C6 H8 O7



L25 ANSWER 14 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:98405 HCAPLUS
DOCUMENT NUMBER: 134:141774
TITLE: Methods, pharmaceutical **compositions** comprising cyclic guanosine 3',5'-monophosphate phosphodiesterase type 5 inhibitors for prophylactic and treatment of diseases and conditions of the eye
INVENTOR(S): Laties, Alan Malev
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 9 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1074258	A2	20010207	EP 2000-306235	20000721 <--
EP 1074258	A3	20010418		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001048788	A2	20010220	JP 2000-222162	20000724 <--
US 2002119974	A1	20020829	US 2002-126375	20020419 <--

PRIORITY APPLN. INFO.: US 1999-146095P P 19990728 <--
US 2000-607562 B1 20000629 <--
OTHER SOURCE(S): MARPAT 134:141774
GI



I

AB The invention describes methods using cyclic guanosine 3',5'-monophosphate phosphodiesterase type 5 inhibitors (I) [R1= H, C1-C3 alkyl, C3-C5 cycloalkyl, perfluoroalkyl; R2= H, (hydroxyl-substituted) C1-C6 alkyl, C3-C6 cycloalkyl, etc.; R3= C1-C6 alkyl, C3-C6 alkenyl, C3-C6 alkynyl, etc.; R4N completes pyrrolidinyl, morpholino, etc.; R5= H, C1-C4 alkyl, C1-C3 alkoxy, etc.] for prophylactic and therapeutic administration in patients with eye diseases and conditions including:central retinal artery occlusion; central retinal vein occlusion; optic neuropathy including, but not limited to, anterior ischemic optic neuropathy and glaucomatous optic neuropathy; and macular (dry) degeneration. Pharmaceutical compns. comprising cyclic guanosine 3',5'-monophosphate phosphodiesterase type 5 inhibitors are also disclosed.

IT **139755-81-0 139755-82-1 139755-83-2**
139755-84-3 139755-85-4 139755-86-5
139755-87-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phosphodiesterase type 5 inhibitors for prophylactic and treatment of eye diseases)

RN 139755-81-0 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-(2-propenyloxy)phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 139755-82-1 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 139755-83-2 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 139755-84-3 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-(1-methyl)- (9CI) (CA INDEX NAME)



RN 139755-85-4 HCAPLUS
CN 1-Piperazineethanol, 4-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 139755-86-5 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 139755-87-6 HCAPLUS
CN 1-Piperazineethanol, 4-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



L25 ANSWER 15 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:63813 HCAPLUS
DOCUMENT NUMBER: 134:136686
TITLE: Pharmaceutical **composition** containing sildenafil derivatives for the treatment of tinnitus and hearing loss
INVENTOR(S): Simon, Shmuel
PATENT ASSIGNEE(S): Israel
SOURCE: PCT Int. Appl., 11 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001005386	A2	20010125	WO 2000-IL405	20000709 <--
WO 2001005386	A3	20010719		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: IL 1999-130968 A 19990715 <--
OTHER SOURCE(S): MARPAT 134:136686
GI



I

AB The present invention relates to the use of sildenafil and related compds. (I; R1, R2, R3, R4 = H, Me, Et, Pr, iso-Pr) or any pharmaceutically acceptable salt thereof, in the prepn. of pharmaceutical **compn.** useful for decreasing or eliminating tinnitus and for decreasing hearing loss. Pharmaceutical compns. contg. drugs of the present inventions are suitable for oral, parenteral, rectal and topical administration. A male patient, suffering for several years from severe tinnitus and hearing loss, was prescribed sildenafil citrate for improving his sexual performance. Unexpectedly, the patient noticed amelioration of the tinnitus, which eventually nearly disappeared. An intentional test was made to stop the medication, which resulted in return of tinnitus within a period of 2-3 wk after from cessation of the sildenafil citrate. A rechallenge with sildenafil citrate, 25 mg twice weekly, again reduced the severity of tinnitus within a week and proceeded to almost complete disappearance of the symptom and improvement in hearing. Also, a female patient, known to have bilateral tinnitus and hearing loss for > 20 yr, was given sildenafil citrate, 25 mg daily. Starting after the 5th daily dose, the patient reported marked redn. in her tinnitus, which persisted for as long as she took the drug.

IT **139755-83-2 171599-83-0**, Sildenafil citrate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. contg. sildenafil and its derivs. for treatment of tinnitus and hearing loss)

RN 139755-83-2 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 171599-83-0 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 77-92-9
CMF C6 H8 O7



L25 ANSWER 16 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:911253 HCAPLUS
DOCUMENT NUMBER: 134:76387
TITLE: Process for preparing sildenafil and troche **composition** containing sildenafil and apomorphine for treatment of erection disorders
INVENTOR(S): Ding, Ding Sheng
PATENT ASSIGNEE(S): Biochemical Pharmaceutical Factory of Zhuhai Sez, Peop. Rep. China
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000078760	A1	20001228	WO 2000-CN145	20000608 <--

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU,

TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: CN 1999-108194 A 19990621 <--

AB The invention relates to a process for the prepn. of sildenafil, a troche which comprises sildenafil and apomorphine for treatment of erection disorders. The process for the synthesis of sildenafil according to the invention comprises the reaction of a pyrazolo[4,3-d]pyrimidine benzenesulfonyl halide with 1-methylpiperazine salt, followed by neutralization. The troche according to the invention comprises apomorphine hydrochloride and sildenafil citrate. The troche **compn.** may contain cyclodextrin or phospholipids. For example, a lozenge **compn.** contained sildenafil citrate 40, apomorphine hydrochloride 6, .beta.-cyclodextrin 150, hydropropyl Me cellulose 6, stearic acid 6, mannitol 28, sucrose 780, aspartame 15, strawberry flavor 5, methylparaben 0.04, camphor 2, and Ca stearate 10 parts.

IT **139755-83-2P**, Sildenafil
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of sildenafil and lozenges contg. sildenafil and apomorphine for treatment of erection dysfunction)

RN 139755-83-2 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



IT **171599-83-0**, Sildenafil citrate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of sildenafil and lozenges contg. sildenafil and apomorphine for treatment of erection dysfunction)

RN 171599-83-0 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 77-92-9
CMF C6 H8 O7



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 17 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:880937 HCAPLUS
DOCUMENT NUMBER: 134:46783
TITLE: Pharmaceutical **compositions** for nasal administration of water-soluble drugs
INVENTOR(S): Klocker, Norbert
PATENT ASSIGNEE(S): Hexal A.-G., Germany
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000074652	A1	20001214	WO 2000-EP4800	20000526 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19925289	A1	20001207	DE 1999-19925289	19990602
DE 19936545	A1	20010208	DE 1999-19936545	19990803
EP 1189596	A1	20020327	EP 2000-935121	20000526 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: DE 1999-19925289 A 19990602 <--
DE 1999-19936545 A 19990803 <--
WO 2000-EP4800 W 20000526 <--

AB The invention relates to a nasally administered pharmaceutical **compn.** comprised of at least 1 water-sol. drug, neutral oil and, optionally, at least one solubilizer, whereby the addn. of preservatives and propellants can be dispensed with. The **compn.** contains essentially no water. Polyhexanide 20 mg was dissolved in 100 mL LMiglyol-812, the soln. was sterilized and filled into a pump-spray.

IT **171599-83-0**, Sildenafil citrate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. for nasal administration of water-sol. drugs)

RN 171599-83-0 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 77-92-9
CMF C6 H8 O7



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 18 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:865097 HCAPLUS
DOCUMENT NUMBER: 134:32988
TITLE: Nasal pharmaceutical **composition** for water-soluble drugs
INVENTOR(S): Kloecker, Norbert
PATENT ASSIGNEE(S): Hexal A.-G., Germany
SOURCE: Ger. Offen., 6 pp.
CODEN: GWXXBX

DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19925289	A1	20001207	DE 1999-19925289	19990602
WO 2000074652	A1	20001214	WO 2000-EP4800	20000526 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1189596	A1	20020327	EP 2000-935121	20000526 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: DE 1999-19925289 A 19990602 <--
DE 1999-19936545 A 19990803 <--
WO 2000-EP4800 W 20000526 <--

AB A pharmaceutical **compn.** for nasal administration consists of at least a water-sol. drug, neutral oil, and a soln. mediator, in which no preservatives and propellants are present and the **compn.** is essentially water-free. Thus, polyhexanide was dissolved in Miglyol-840 and the **compn.** was sterilized and filled into a pump spray.

IT **171599-83-0**, Sildenafil citrate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nasal pharmaceutical **compn.** for water-sol. drugs)

RN 171599-83-0 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 77-92-9
CMF C6 H8 O7



L25 ANSWER 19 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:725436 HCAPLUS
DOCUMENT NUMBER: 133:301171
TITLE: **Compositions** and methods for improved delivery of ionizable hydrophobic therapeutic agents
INVENTOR(S): Chen, Feng-jing; Patel, Manesh V.
PATENT ASSIGNEE(S): Lipocine, Inc., USA
SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059475	A1	20001012	WO 2000-US7342	20000316 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6383471	B1	20020507	US 1999-287043	19990406
EP 1165048	A1	20020102	EP 2000-916547	20000316 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: US 1999-287043 A 19990406 <--
WO 2000-US7342 W 20000316 <--

AB The present invention is directed to a pharmaceutical **compn.** including a hydrophobic therapeutic agent having at least one ionizable functional group, and a carrier. The carrier includes an ionizing agent capable of ionizing the functional group, a surfactant, and optionally solubilizers, triglycerides, and neutralizing agents. The invention further relates to a method of prepg. such compns. by providing a **compn.** of an ionizable hydrophobic therapeutic agent, an ionizing agent, and a surfactant, and neutralizing a portion of the ionizing agent with a neutralizing agent. The compns. of the invention are particularly suitable for use in oral dosage forms. A carrier contg. concd. phosphoric acid 0.025, Tween-20 0.3, Arlacel 186 0.2, sodium taurocholate 0.15, propylene glycol 0.3 g was formulated. Itraconazole was included in the carrier at 30 mg/mL for testing the stability of the itraconazole soln. upon diln. in simulated gastric fluid.

IT **139755-83-2**, Sildenafil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

RN 139755-83-2 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 20 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:666604 HCAPLUS
DOCUMENT NUMBER: 133:242681
TITLE: Controlled release of sildenafil delivered by sublingual or buccal administration
INVENTOR(S): El-Rashidy, Ragab
PATENT ASSIGNEE(S): Pentech Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000054777	A1	20000921	WO 2000-US6662	20000314 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1171134	A1	20020116	EP 2000-916328	20000314 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: US 1999-268957 A 19990316 <--
WO 2000-US6662 W 20000314 <--

AB Disclosed is a controlled release **compn.** contg. sildenafil for delivery via the sublingual or buccal routes. In addn. to sildenafil, the **compn.** includes an osmotic agent, a swellable hydrophilic carrier, and a water-dispersible polymer. A tablet contained sildenafil citrate 20, ascorbic acid 3, citric acid 2, microcryst. cellulose 22.7, Mg stearate 1.2, hydroxypropyl Me cellulose 5, D&C Yellow Aluminum Lake 0.1, aspartame 1, and mannitol 21 mg.

IT **139755-83-2**, Sildenafil **171599-83-0**, Sildenafil citrate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled-release tablet formulation of sildenafil for sublingual or

buccal administration)
RN 139755-83-2 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 171599-83-0 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 77-92-9
CMF C6 H8 O7



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 21 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:666601 HCAPLUS
DOCUMENT NUMBER: 133:256811

TITLE: Pharmaceutical **compositions** containing dopamine agonists in combination with nitric oxide donors for treating and/or preventing sexual dysfunctions
INVENTOR(S): Garvey, David S.
PATENT ASSIGNEE(S): Nitromed, Inc., USA
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000054773	A1	20000921	WO 2000-US3709	20000310 <--

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-123920P P 19990312 <--
OTHER SOURCE(S): MARPAT 133:256811

AB The present invention is directed to novel compns. comprising at least one dopamine agonist in combination with at least one nitric oxide donor (i.e. compds. that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or are substrates for nitric oxide synthase). The novel compns. may optionally comprise at least one therapeutic agent, such as, a vasoactive agent, an antiemetic agent, and mixts. thereof. The dopamine agonist is preferably apomorphine. The present invention is also directed to methods for treating and/or preventing sexual dysfunctions and/or enhancing sexual responses in patients. In other embodiments, the present invention is directed to methods treating or preventing neurodegenerative diseases, mitochondrial diseases, spinal cord injury, central or psychostimulant addiction, senile dementia, circulatory disorders, cardiovascular disorders, hyperprolactinemia or myopia. The compds. and/or compns. of the present invention can also be provided in the form of a pharmaceutical kit (no data).

IT **139755-83-2**, Sildenafil
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. contg. dopamine agonists in combination with nitric oxide donors for treating and/or preventing sexual dysfunctions)

RN 139755-83-2 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 22 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:645819 HCAPLUS
DOCUMENT NUMBER: 133:227820
TITLE: Pharmaceutical **compositions** for treating erectile dysfunction containing a melanocortin receptor agonist and a cyclic-GMP-specific phosphodiesterase inhibitor or an .alpha.-adrenergic receptor antagonist
INVENTOR(S): Stoner, Elizabeth
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Waldstreicher, Joanne
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000053148	A2	20000914	WO 2000-US5711	20000303 <--
WO 2000053148	A3	20001214		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1161255	A2	20011212	EP 2000-916081	20000303 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: US 1999-123244P P 19990308 <--
WO 2000-US5711 W 20000303 <--

AB The present invention provides for a method for the treatment of erectile dysfunction in a male or female human subject in need of such treatment comprising administration of a therapeutically effective amt. of an agonist of the melanocortin receptor in combination with a therapeutically effective amt. of a cyclic-GMP-specific phosphodiesterase inhibitor or an alpha-adrenergic receptor antagonist. Further, the present invention provides for pharmaceutical compns. useful in the methods of the present invention, as well as a method of manuf. of a medicament useful for treating erectile dysfunction. Effect of the combination of 20 mg/kg of the invention compds. was tested in rats. A hard gelatin capsule

contained a melanocortin receptor agonist 5, and a type V phosphodiesterase inhibitor 10 mg.

IT **171599-83-0**, Sildenafil citrate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. for treating erectile dysfunction contg. melanocortin receptor agonist and cyclic-GMP-specific phosphodiesterase inhibitor or .alpha.-adrenergic receptor antagonist)

RN 171599-83-0 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 77-92-9
CMF C6 H8 O7



L25 ANSWER 23 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:610555 HCAPLUS
DOCUMENT NUMBER: 133:168355
TITLE: **Compositions** comprising bupropion for the treatment of premature ejaculation
INVENTOR(S): Grassler, Frank Peter
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: Brit. UK Pat. Appl., 11 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2340037	A1	20000216	GB 1999-17346	19990726 <--

PRIORITY APPLN. INFO.: US 1998-94701P P 19980730 <--

AB A **compn.** comprising bupropion or physiol. acceptable salts, solvates, or enantiomers thereof, is used for the treatment of premature ejaculation that is either caused by a phys. disorder or that is induced by a cGMP phosphodiesterase inhibitor or a cGMP phosphodiesterase V inhibitor, such as sildenafil. The **compn.** may comprise bupropion and sildenafil for the treatment of erectile dysfunction and sildenafil-induced premature ejaculation.

IT **139755-83-2**, Sildenafil
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study) (bupropion for treatment of premature ejaculation induced by cGMP phosphodiesterase inhibitor)

RN 139755-83-2 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



L25 ANSWER 24 OF 42 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:608551 HCAPLUS
DOCUMENT NUMBER: 133:213151
TITLE: Pharmaceutical **compositions** and methods for improved delivery of hydrophobic therapeutic agents
INVENTOR(S): Patel, Manesh V.; Chen, Feng-Jing
PATENT ASSIGNEE(S): Lipocine, Inc., USA
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000050007	A1	20000831	WO 2000-US165	20000105 <--
US 6294192	B1	20010925	US 1999-258654	19990226

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1158959 A1 20011205 EP 2000-901394 20000105 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
US 2002012680 A1 20020131 US 2001-898553 20010702 <--
US 6451339 B2 20020917
PRIORITY APPLN. INFO.: US 1999-258654 A 19990226 <--
WO 2000-US165 W 20000105 <--

AB The present invention relates to triglyceride-free pharmaceutical compns. for delivery of hydrophobic therapeutic agents. Compns. of the present invention include a hydrophobic therapeutic agent and a carrier, where the carrier is formed from a combination of a hydrophilic surfactant and a hydrophobic surfactant. Upon diln. with an aq. solvent, the **compn**. forms a clear, aq. dispersion of the surfactants contg. the therapeutic agent. The invention also provides methods of treatment with hydrophobic therapeutic agents using these compns. A pharmaceutical **compn.** contained cyclosporin 0.14, Cremophor RH-40 0.41, Arlacel186 0.29, sodium taurocholate 0.26, and propylene glycol 0.46 mg.

IT **171599-83-0**, Sildenafil citrate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)

RN 171599-83-0 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 77-92-9
CMF C6 H8 O7



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 25 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:553395 HCAPLUS
DOCUMENT NUMBER: 133:155456
TITLE: Topical sprays containing film-forming polymers
INVENTOR(S): Lulla, Amar; Malhotra, Geena; Raut, Preeti
PATENT ASSIGNEE(S): Cipla Limited, India
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000045795	A2	20000810	WO 2000-GB366	20000207 <--
WO 2000045795	A3	20010809		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000007997	A	20011030	BR 2000-7997	20000207 <--
EP 1150661	A2	20011107	EP 2000-902727	20000207 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
ZA 2000005727	A	20001221	ZA 2000-5727	20001017 <--
NO 2001003815	A	20011002	NO 2001-3815	20010803 <--

PRIORITY APPLN. INFO.:

IN 1999-BO92	A	19990205	<--
IN 1999-BO93	A	19990205	<--
IN 1999-BO382	A	19990520	<--
IN 1999-BO582	A	19990817	<--
WO 1999-GB2998	W	19990909	<--
IN 2000-BO43	A	20000113	<--
IN 2000-BO44	A	20000113	<--
WO 2000-GB366	W	20000207	<--

AB A topical, medicinal spray **compn**. comprises one or more medicaments in a volatile vehicle, and one or more film-forming polymers. When sprayed on a topical site, the **compn**. forms a stable, breathable film from which the medicaments are transdermally available. Preferably, the **compn**. comprises 0.1-30 % of one or more medicaments, 0.1-15 % film-forming polymers, 0.1-10 % solubilizers, 0.1-8 % permeation enhancers, 1.0-10 % plasticizers, and a vehicle q.s. 100 %. The invention includes a spray dispenser contg. the topical **compn**. An aerosol contained estradiol 2, PVP K-30 6, vinylacetate-vinylpyrrolidone copolymer 4, vitamin E 1, polyethylene glycol-6000 2, polyethylene glycol 3, dichlorodifluoromethane 24.9, and trichloromonofluoromethane 57.1 %.

IT **139755-83-2**, Sildenafil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical sprays contg. film-forming polymers)

RN 139755-83-2 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



L25 ANSWER 26 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:534979 HCAPLUS
DOCUMENT NUMBER: 133:140265
TITLE: Desmethylsildenafil **compositions** and methods
INVENTOR(S): Yelle, William E.
PATENT ASSIGNEE(S): Sepracor Inc., USA
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000044363	A2	20000803	WO 2000-US1470	20000121 <--

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-117611P P 19990128 <--

AB Methods and compns. are disclosed utilizing desmethylsildenafil for the treatment of sexual dysfunction in humans. Desmethylsildenafil exhibits a lessened liability toward drug-drug interactions than sildenafil and a more predictable dosing regimen than sildenafil. Desmethylsildenafil is also useful for the treatment of angina, hypertension, heart failure or atherosclerosis. Tablets were prepd. contg. 20 mg desmethylsildenafil.

IT **139755-82-1**, Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(desmethylsildenafil oral pharmaceuticals for sexual dysfunction treatment)

RN 139755-82-1 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



L25 ANSWER 27 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:513484 HCAPLUS
DOCUMENT NUMBER: 133:125303
TITLE: **Compositions** and methods for mucosal delivery
INVENTOR(S): Chen, Li-Lan H.; Pfister, William R.; Renn, Donald W.; Buranachokpaisan, Thitiwan; Osborne, James; Tan, Hock Seng; Tao, Li
PATENT ASSIGNEE(S): Lavipharm Laboratories, Inc., USA
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000042992	A2	20000727	WO 1999-US31327	19991230 <--
WO 2000042992	A3	20001019		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 9917089	A	20011016	BR 1999-17089	19991230 <--
EP 1143940	A2	20011017	EP 1999-966737	19991230 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NO 2001003536	A	20010920	NO 2001-3536	20010717 <--

PRIORITY APPLN. INFO.:			
US 1999-116823P	P	19990121	<--
US 1999-434878	A	19991105	<--
WO 1999-US31327	W	19991230	<--

AB A dosage unit comprising a water-sol. hydrocolloid and a mucosal surface-coat-forming film, such film including an ED of active agent. In the dosage unit sildenafil citrate, nicotine, hydromorphone, oxybutynin or estradiol are used as active agents. A **compn**. was prepd. contg.Methocel E5 21.06, propylene glycol 1.0, Aspartame 0.8, peppermint 1.0, citric acid 0.7, Cremphor EL40 1.0, benzoic acid 0.013, dyes qs. and water 74.42 wt.%.

IT **171599-83-0**, Sildenafil citrate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for mucosal delivery)

RN 171599-83-0 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 77-92-9
CMF C6 H8 O7



L25 ANSWER 28 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:464581 HCAPLUS
DOCUMENT NUMBER: 133:94529
TITLE: Apomorphine and sildenafil **composition**
INVENTOR(S): El-rashidy, Ragab
PATENT ASSIGNEE(S): Pentech Pharmaceuticals, Inc., USA
SOURCE: U.S., 10 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6087362	A	20000711	US 1999-270035	19990316
WO 2000054774	A1	20000921	WO 2000-US6654	20000314 <--

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1173178 A1 20020123 EP 2000-916324 20000314 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

BR 2000009016 A 20020416 BR 2000-9016 20000314 <--
NO 2001004519 A 20011025 NO 2001-4519 20010917 <--
PRIORITY APPLN. INFO.: US 1999-270035 A 19990316 <--
WO 2000-US6654 W 20000314 <--

AB The treatment of sexual dysfunction in human patients by an oral therapy regimen of administration of apomorphine and sildenafil is disclosed. This treatment optimizes the efficacy of each drug and substantially minimizes the undesirable side effects assocd. individually therewith. Apomorphine and sildenafil can be co-administered with a combination dosage unit or administered sequentially in sep. dosage units, substantially prior to sexual activity. Other erectogenic agents can be administered along with apomorphine and sildenafil.

IT **139755-83-2**, Sildenafil **171599-83-0**, Sildenafil citrate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tablets contg. apomorphine and sildenafil and erectogenic agents for treatment of sexual dysfunction)

RN 139755-83-2 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 171599-83-0 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 77-92-9
CMF C6 H8 O7



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 29 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:456860 HCAPLUS
DOCUMENT NUMBER: 133:79357
TITLE: Dosage forms comprising porous particles
INVENTOR(S): Wong, Patrick; Edgren, David; Dong, Liang-chang; Pollock-Dove, Crystal
PATENT ASSIGNEE(S): Alza Corp., USA; Allan, Jamie
SOURCE: PCT Int. Appl., 174 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000038655	A1	20000706	WO 1999-GB4426	19991223 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6342249	B1	20020129	US 1999-470088	19991222 <--
EP 1140027	A1	20011010	EP 1999-962459	19991223 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002533380	T2	20021008	JP 2000-590609	19991223 <--

US 2002086055 A1 20020704 US 2001-22300 20011214 <--
PRIORITY APPLN. INFO.: US 1998-113559P P 19981223 <--
US 1998-113615P P 19981223 <--
US 1998-113750P P 19981223 <--
US 1999-470088 A1 19991222 <--
WO 1999-GB4426 W 19991223 <--

AB The invention relates to a dosage form comprising a plurality of particles having interior pores and a liq., active agent formulation in the pores, the particles being compactable and adapted to retain substantially all of the liq. active agent formulation within the pores during the compacting process. The dosage forms may be in the forms of unitary oral forms for immediate release of active agent, prolonged delivery forms, or controlled delivery forms. All forms involve certain absorbent materials having prescribed characteristics, particularly spray-dried calcium hydrogen phosphate and magnesium aluminometasilicate. Sildenafil citrate 70 g was mixed with 280 g propylene glycol and the mixt. was added to 550 g CaHPO4 particles. Low-substituted hydroxypropyl cellulose 100 g was added to the above blend and the resulting formulation was compressed to give tablets (contg. 25 mg sildenafil citrate each), which were film coated with a **compn**. contg. hydroxypropyl Me cellulose and polyethylene glycol at the wt. ratio of 75 to 25 parts.

IT **171599-83-0**, Sildenafil citrate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral dosage forms comprising porous absorbent particles)

RN 171599-83-0 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 77-92-9
CMF C6 H8 O7



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 30 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:420947 HCAPLUS
DOCUMENT NUMBER: 133:63952
TITLE: **Compositions** containing nitric oxide donor and phosphodiesterase inhibitors for the treatment of anorectal disorders
INVENTOR(S): Parks, Thomas P.; Mak, Vivien; Lee, Jung-chung; Lee, Charles
PATENT ASSIGNEE(S): Cellegy Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035434	A2	20000622	WO 1999-US29459	19991213 <--
WO 2000035434	A3	20001130		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000021763	A5	20000703	AU 2000-21763	19991213 <--
BR 9916162	A	20010904	BR 1999-16162	19991213 <--
EP 1143956	A2	20011017	EP 1999-966154	19991213 <--
EP 1143956	A3	20011212		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, LT, FI				
NO 2001002916	A	20010814	NO 2001-2916	20010613 <--

PRIORITY APPLN. INFO.:
US 1998-112325P P 19981214 <--
US 1999-139916P P 19990617 <--
US 1999-155318P P 19990921 <--
WO 1999-US29459 W 19991213 <--

AB Compns. and methods for the treatment of anorectal disorders are provided in which certain combinations of NO donors, PDE inhibitors, superoxide (O2-) scavengers, .beta.-adrenergic agonists, cAMP-dependent protein kinase activators, .alpha.1-adrenergic antagonists, L-type Ca2+ channel blockers, estrogens, ATP-sensitive K+ channel activators and smooth muscle relaxants are used. 7A topical **compn.** contained sildenafil 0.05-1, white petrolatum 75, paraffin wax 4, lanolin 14, and sorbitan sesquioleate 2, and propylene glycol 4% by wt.

IT **139755-83-2**, Sildenafil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. contg. nitric oxide donor and phosphodiesterase inhibitors for treatment of anorectal disorders)

RN 139755-83-2 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



L25 ANSWER 31 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:290577 HCAPLUS
DOCUMENT NUMBER: 132:329928
TITLE: Cyclooxygenase inhibition- and phosphodiesterase inhibition-based methods for identifying antineoplastic compds., and pharmaceutical compns.
INVENTOR(S): Liu, Li; Zhu, Bing; Han, Li; Thompson, Joseph W.; Pamukeu, Rifat; Piazza, Gary A.
PATENT ASSIGNEE(S): Cell Pathways, Inc., USA
SOURCE: Eur. Pat. Appl., 65 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
EP 997145	A1	20000503	EP 1999-308129	19991014	<--
EP 997145	B1	20020327			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
US 6200771	B1	20010313	US 1998-173375	19981015	
US 6130053	A	20001010	US 1999-366003	19990803	
US 2002009764	A1	20020124	US 1999-414628	19991008	
NO 9904995	A	20000417	NO 1999-4995	19991014	<--
ZA 9906508	A	20000418	ZA 1999-6508	19991014	<--
AU 9954010	A1	20000420	AU 1999-54010	19991014	<--
EP 1161943	A2	20011212	EP 2001-119687	19991014	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
AT 214920	E	20020415	AT 1999-308129	19991014	<--
CN 1255379	A	20000607	CN 1999-121818	19991015	<--
JP 2000186047	A2	20000704	JP 1999-330364	19991015	<--

PRIORITY APPLN. INFO.:			
US 1998-173375	A	19981015	<--
US 1999-366003	A	19990803	<--
US 1999-414628	A	19991008	<--
EP 1999-308129	A3	19991014	<--

AB A pharmaceutical **compn.** is disclosed for the treatment of neoplasia which comprises a pharmaceutically acceptable carrier and a compd. selected by (1) detg. the cyclooxygenase (COX) inhibitory activity of the compd; (2) detg. the phosphodiesterase (PDE) inhibition activity of the compd., in which the PDE is characterized by (a) cGMP specificity over cAMP, (b) pos. cooperative kinetic behavior in the presence of cGMP substrate, (c) submicromolar affinity for cGMP, and (d) insensitivity to incubation with purified cGMP-dependent protein kinase; and (3) selecting the compd. that has COX inhibitory activity lower than the PDE activity

for treating neoplasia. Also provided is a method for selecting a compd. for the treatment of neoplasia which comprises (1) detg. the COX inhibitory activity of the compd.; (2) detg. the PDE2 inhibition activity of the compd.; and (3) selecting the compd. that has COX inhibitory activity lower than the PDE activity for treating neoplasia. Isolation of a novel cGMP-specific PDE (appearing to be a novel conformation of PDE2) from neoplastic cells is described.

IT **139755-83-2**, Sildenafil
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(cyclooxygenase inhibition- and phosphodiesterase inhibition-based methods for identifying antineoplastic compds., and pharmaceutical compns.)

RN 139755-83-2 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 32 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:277834 HCAPLUS
DOCUMENT NUMBER: 132:288784
TITLE: The use of dopaminergic agents in the management of sexual dysfunction
INVENTOR(S): Karpati, George; Molnar, Maria Jutka
PATENT ASSIGNEE(S): Mcgill University, Can.
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000023056	A2	20000427	WO 1999-CA977	19991020 <--
WO 2000023056	A3	20000824		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9963218 A1 20000508 AU 1999-63218 19991020 <--
PRIORITY APPLN. INFO.: CA 1998-2251255 A 19981020 <--
WO 1999-CA977 W 19991020 <--

AB This invention relates to a new use of dopaminergic agonists for improving sexual function, particularly erectile function. Preferred agonists are pramipexole and ropinirole which present much less side effects than agonists of previous generations. Pramipexole has been further used successfully in combination with sildenafil. A new pharmaceutical **compn.** comprising both a vasodilating agent such as sildenafil and a dopaminergic agonist is described and claimed.

IT **139755-83-2**, Sildenafil
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of dopaminergic agents in the management of sexual dysfunction)

RN 139755-83-2 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



L25 ANSWER 33 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:190932 HCAPLUS
DOCUMENT NUMBER: 132:227470
TITLE: Pharmaceutical **compositions** containing phentolamine, papaverine, and alprostadil for the treatment of male erectile dysfunction
INVENTOR(S): Podolski, Joseph S.
PATENT ASSIGNEE(S): Zonagen, Inc., USA
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000015233	A1	20000323	WO 1999-US21513	19990917 <--

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9959270 A1 20000403 AU 1999-59270 19990917 <--
EP 1112075 A1 20010704 EP 1999-946977 19990917 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
JP 2002524520 T2 20020806 JP 2000-569817 19990917 <--
PRIORITY APPLN. INFO.: US 1998-154677 A2 19980917 <--
WO 1999-US21513 W 19990917 <--

AB Improved drug compns. and methods useful in the treatment of male erectile dysfunction. An optimized mixt. of the drugs phentolamine mesylate, papaverine hydrochloride, and alprostadil in a buffer contg. L-arginine and glycine is to be injected into the penile tissue to produce an erection in otherwise impotent men. An injection soln. contained prostaglandin E1 0.005, phentolamine mesylate 5.0, papaverine.HCl 7.5, L-arginine 0.35, glycine 7.5, mannitol 24, benzyl alc. 8.4 mg., final pH = 4.01. Male patients who failed oral treatment were injected with 0.5 mL of the above soln. into the corpus cavernosum through the dorsal aspect of penis. The % of the patients able to achieve a full erection following the injection was 42%.

IT **139755-83-2**, Sildenafil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. contg. phentolamine, papaverine, and alprostadil for treatment of male erectile dysfunction)

RN 139755-83-2 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 34 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:84582 HCAPLUS
DOCUMENT NUMBER: 132:141949
TITLE: Preparation of aqueous clear solution dosage forms with bile acids
INVENTOR(S): Yoo, Seo Hong
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000004875	A2	20000203	WO 1999-US12840	19990720 <--
WO 2000004875	A3	20010503		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9950819	A1	20000214	AU 1999-50819	19990720	<--
EP 1113785	A2	20010711	EP 1999-935313	19990720	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
BR 9912395	A	20011016	BR 1999-12395	19990720	<--
JP 2002522357	T2	20020723	JP 2000-560868	19990720	<--
PRIORITY APPLN. INFO.:			US 1998-94069P P	19980724	<--
			WO 1999-US12840 W	19990720	<--

AB Compns. for pharmaceutical and other uses for prepg. clear aq. solns. contg. bile acids which do not form ppts. over selected ranges of pH values of the aq. soln. and methods of making such solns. are disclosed. The compns. of the invention comprise water; a bile acid in the form of a bile acid, bile acid salt, or a bile acid conjugated with an amine by an amide linkage; and a high mol. wt. aq. sol. starch conversion product. The **compn**. remains in soln. without forming a ppt. over a range of pH values and, according to one embodiment, remains in soln. all pH values obtainable in an aq. system. The **compn**., according to some embodiments, may further contain a pharmaceutical compd. in a pharmaceutically effective amt. A pharmaceutical soln. which did not show any pptn. at any pH contained 3.alpha.-7.beta.-dihydroxy-5.beta.-cholanic acid 200 mg, maltodextrin 5, preservatives q.s., flavoring agent q.s., sweetener q.s., and water q.s. 100 mL.

IT **139755-83-2**, Sildenafil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of aq. clear soln. dosage forms with bile acids)

RN 139755-83-2 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



L25 ANSWER 35 OF 42 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:	2000:83199 HCAPLUS
DOCUMENT NUMBER:	132:113122
TITLE:	Water-soluble tablet containing sildenafil
INVENTOR(S):	Struengmann, Thomas
PATENT ASSIGNEE(S):	Hexal A.-G., Germany
SOURCE:	Ger. Offen., 4 pp.
	CODEN: GWXXBX

DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19834507	A1	20000203	DE 1998-19834507	19980731
WO 2000007596	A1	20000217	WO 1999-EP5464	19990730 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9954156	A1	20000228	AU 1999-54156	19990730 <--

PRIORITY APPLN. INFO.: DE 1998-19834507 A 19980731 <--
WO 1999-EP5464 W 19990730 <--

AB Sildenafil (Viagra) or 1 of its pharmaceutically acceptable salts is administered in a water-sol. tablet formulation to hasten its onset of action in inducing an erection. The **compn.** may addnl. contain a cytochrome P 450 inhibitor to decrease the rate of sildenafil metab. and increase its plasma concn. The **compn.** is resorbed well, and patient compliance is good.

IT **139755-83-2**, Sildenafil **171599-83-0**, Sildenafil citrate
252920-86-8 255885-45-1 255885-46-2
255885-47-3 255885-48-4 255885-49-5
255885-50-8 255885-51-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(water-sol. tablet contg. sildenafil)

RN 139755-83-2 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 171599-83-0 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 77-92-9
CMF C6 H8 O7



RN 252920-86-8 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 255885-45-1 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, sulfate (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 7664-93-9
CMF H2 O4 S



RN 255885-46-2 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, phosphate (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 7664-38-2
CMF H3 O4 P



RN 255885-47-3 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 255885-48-4 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 255885-49-5 HCAPLUS
CN Butanedioic acid, compd. with 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 110-15-6
CMF C4 H6 O4



RN 255885-50-8 HCAPLUS
CN L-Ascorbic acid, compd. with 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-

pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 50-81-7
CMF C6 H8 O6

Absolute stereochemistry.



RN 255885-51-9 HCAPLUS
CN Carbonic acid, compd. with 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 463-79-6
CMF C H2 O3



L25 ANSWER 36 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:83198 HCAPLUS
DOCUMENT NUMBER: 132:113121
TITLE: Transmucosal therapeutic system for the use of sildenafil
INVENTOR(S): Struengmann, Thomas
PATENT ASSIGNEE(S): Hexal A.-G., Germany
SOURCE: Ger. Offen., 4 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19834506	A1	20000203	DE 1998-19834506	19980731
WO 2000007597	A1	20000217	WO 1999-EP5465	19990730 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9952898	A1	20000228	AU 1999-52898	19990730 <--

PRIORITY APPLN. INFO.: DE 1998-19834506 A 19980731 <--
WO 1999-EP5465 W 19990730 <--

AB Sildenafil (Viagra) or 1 of its pharmaceutically acceptable salts is administered transmucosally as a spray, cream, gel, powder, or drops to hasten its onset of action in inducing an erection. This mode of administration improves the drug bioavailability and thereby decreases the dosage required and the risk of side effects. The **compn.** may addnl. contain a cytochrome P 450 inhibitor to decrease the rate of sildenafil metab. and increase its plasma concn. The **compn.** does not irritate the mucosa.

IT **139755-83-2**, Sildenafil **171599-83-0**, Sildenafil citrate **252920-86-8 255885-45-1 255885-46-2 255885-47-3 255885-48-4 255885-49-5 255885-50-8 255885-51-9**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transmucosal therapeutic system for use of sildenafil)

RN 139755-83-2 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-

d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 171599-83-0 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 77-92-9
CMF C6 H8 O7



RN 252920-86-8 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 255885-45-1 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, sulfate (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 7664-93-9
CMF H2 O4 S



RN 255885-46-2 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, phosphate (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2

CMF C22 H30 N6 O4 S



CM 2

CRN 7664-38-2
CMF H3 O4 P



RN 255885-47-3 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 255885-48-4 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 255885-49-5 HCAPLUS
CN Butanedioic acid, compd. with 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 110-15-6
CMF C4 H6 O4



RN 255885-50-8 HCAPLUS
CN L-Ascorbic acid, compd. with 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 50-81-7
CMF C6 H8 O6

Absolute stereochemistry.



RN 255885-51-9 HCAPLUS
CN Carbonic acid, compd. with 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 463-79-6
CMF C H2 O3



L25 ANSWER 37 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:763835 HCAPLUS
DOCUMENT NUMBER: 132:26843
TITLE: Compounds, **compositions** and methods for treating erectile dysfunction
INVENTOR(S): Shoemaker, James D.
PATENT ASSIGNEE(S): Saint Louis University, USA
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9960985	A2	19991202	WO 1999-US11589	19990526 <--
WO 9960985	A3	20000217		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6124461	A	20000926	US 1998-84849	19980526
AU 9943141	A1	19991213	AU 1999-43141	19990526 <--

PRIORITY APPLN. INFO.: US 1998-84849 A 19980526 <--
WO 1999-US11589 W 19990526 <--

AB Vasoactive compds. are described for the treatment of erectile dysfunction and impotence. The compds. are reaction products of an anionic or neg. charged vasoactive or erection-inducing component and a cationic or pos. charged vasoactive or erection-inducing component. These components are combined as acids and bases to form an org. salt or ionically bonded compd. The compds. have advantageous soly. characteristics and efficacy. A compd. of the invention is combined with a pharmaceutical vehicle to form a **compn.** which preferably includes an emulsifier. A local anesthetic and/or androgenic steroids may also be included. Compns. of the invention may also include more than vasoactive org. salt compd. The **compn.** can be advantageously formulated and administered to allow self-adjusted dosing, while minimizing or preventing overdosing. Phentolamine alprostadilate and papaverine alprostadilate, both existing as compds., not mixts., were prepd. and formulated into pharmaceutical compns.

IT **139755-83-2**, Sildenafil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phentolamine alprostadilate and papaverine alprostadilate compns. for treatment of erectile dysfunction)

RN 139755-83-2 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



L25 ANSWER 38 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:659253 HCAPLUS
DOCUMENT NUMBER: 131:291292
TITLE: Pharmaceutical **compositions** comprising L-arginine, ginseng and Ginkgo biloba for enhancing blood circulation
INVENTOR(S): Wuh, Hank C. K.; Trant, Aileen S.; Kwock, Denny W.

PATENT ASSIGNEE(S): The Daily Wellness Company, USA
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 9951252	A1	19991014	WO 1999-US7427	19990402	<--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
AU 9932215	A1	19991025	AU 1999-32215	19990402	<--
US 6368640	B1	20020409	US 1999-410446	19991001	<--

PRIORITY APPLN. INFO.:
US 1998-80009P P 19980403 <--
US 1998-93164P P 19980717 <--
WO 1999-US7427 W 19990402 <--

AB The invention provides methods and compns. for maintaining a state of wellness in a human by providing a dietary supplement comprising L-arginine, in combination with ginseng and Ginkgo biloba and/or addnl. nutritional supplements. The invention provides a unique blend of components that, in combination, synergistically bestow cardiac and sexual wellness upon a human when taken regularly as a dietary supplement alone, or in combination with a pharmaceutical **compn.** (e.g. Viagra), which facilitates smooth muscle relaxation and vascular dilatation. A dietary supplement in a gel cap contained vitamin A 5000, vitamin E 30 IU, vitamin C 60, thiamin 1.5, riboflavin 1.7, niacin 20, vitamin B6 2, pantothenic acid 10, zinc 15, L-arginine 3000, American ginseng (5% ginsenosides) 100 mg, Korean ginseng (30% standardized) 100, Ginkgo biloba (24% flavone glycosides, 6% terpene lactones) 50 mg, folate 400, vitamin B12 6, biotin 300, selenium 70 .mu.g, and excipients q.s. Efficacy of the **compn.** in men with erectile dysfunction is reported.

IT **171599-83-0**, Sildenafil citrate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. comprising arginine, ginseng and Ginkgo biloba for enhancing blood circulation)

RN 171599-83-0 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 77-92-9
CMF C6 H8 O7



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 39 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:622282 HCAPLUS
DOCUMENT NUMBER: 131:252588
TITLE: Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, **compositions**, and use in treating sexual dysfunctions
INVENTOR(S): Garvey, David S.; Saenz de Tejada, Inigo
PATENT ASSIGNEE(S): Nitromed, Inc., USA
SOURCE: U.S., 49 pp., Cont.-in-part of U.S. 5,874,437. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 5958926	A	19990928	US 1998-145142	19980901	<--
US 5874437	A	19990223	US 1996-740764	19961101	
US 6133272	A	20001017	US 1999-241281	19990201	<--
US 6172060	B1	20010109	US 1999-247296	19990210	<--
US 6172068	B1	20010109	US 1999-247322	19990210	<--
US 6177428	B1	20010123	US 1999-247321	19990210	<--
US 6197782	B1	20010306	US 1999-247295	19990210	<--
US 6197778	B1	20010306	US 1999-247320	19990210	<--
US 6221881	B1	20010424	US 1999-247292	19990210	<--
US 6232321	B1	20010515	US 1999-247293	19990210	<--
US 6316457	B1	20011113	US 1999-247323	19990210	<--
US 6211179	B1	20010403	US 1999-347426	19990706	<--
WO 2000012076	A1	20000309	WO 1999-US20024	19990901	<--

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,

CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9961334	A1	20000321	AU 1999-61334	19990901	<--
EP 1109543	A1	20010627	EP 1999-948093	19990901	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
US 6331543	B1	20011218	US 1999-387727	19990901	<--
JP 2002523450	T2	20020730	JP 2000-567194	19990901	<--
US 2002019405	A1	20020214	US 2001-941691	20010830	<--
US 6462044	B2	20021008			

PRIORITY APPLN. INFO.:

US 1996-740764	A2	19961101	<--
WO 1997-US19870	A2	19971031	<--
US 1998-145142	A3	19980901	<--
US 1999-387727	A1	19990901	<--
WO 1999-US20024	W	19990901	<--

OTHER SOURCE(S): MARPAT 131:252588

AB Disclosed are nitrosated and/or nitrosylated phosphodiesterase inhibitors having the formula NOn-(PDE inhibitor) (n = 1, 2). The invention also provides compns. comprising such compds. in a pharmaceutically acceptable carrier. The invention further provides a **compn.** comprising a therapeutically effective amt. of an phosphodiesterase inhibitor (PDE inhibitor), which can optionally be substituted with at least one NO or NO2 moiety, and 1-10-fold molar excess of a compd. that donates, transfers, or releases nitrogen monoxide as a charged species, i.e., nitrosonium (NO+) or nitroxyl (NO-), or as the neutral species, nitric oxide (NO.cntdot.) or which stimulates endogenous endothelium-derived relaxing factor prodn. The invention also provides compns. comprising such compds. in a pharmaceutically acceptable carrier. The invention also provides methods for treating sexual dysfunctions in males and females.

IT **139755-83-2D**, Sildenafil, nitrosated and nitrosylated derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nitrosated and nitrosylated phosphodiesterase inhibitor compds., compns., and use in treating sexual dysfunctions)

RN 139755-83-2 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 40 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:401692 HCAPLUS
DOCUMENT NUMBER: 131:49481
TITLE: Combination effective for the treatment of impotence
INVENTOR(S): Wyllie, Michael Grant
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 9930697	A2	19990624	WO 1998-IB1723	19981029	<--
WO 9930697	A3	19990826			
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2314993	AA	19990624	CA 1998-2314993	19981029	<--
AU 9894558	A1	19990705	AU 1998-94558	19981029	<--
EP 1037616	A2	20000927	EP 1998-947741	19981029	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
BR 9813699	A	20001010	BR 1998-13699	19981029	<--
JP 2002508315	T2	20020319	JP 2000-538680	19981029	<--
ZA 9811507	A	20000619	ZA 1998-11507	19981215	<--
NO 2000003065	A	20000815	NO 2000-3065	20000615	<--

PRIORITY APPLN. INFO.: US 1997-69741P P 19971216 <--
WO 1998-IB1723 W 19981029 <--

OTHER SOURCE(S): MARPAT 131:49481

AB The invention relates to the treatment of erectile dysfunction with a combination of (1) a compd. selected from .alpha.-adrenergic receptor antagonists and (2) a compd. selected from agents which elevate cGMP levels. Sildenafil or a pharmaceutically acceptable salt thereof is preferred as the cGMP PDE elevator. Also included are compns. and kits comprising such impotence treating compds. For example, an oral **compn**. contains the combination of doxazosin mesylate and sildenafil citrate.

IT **139755-83-2 171599-83-0**, Sildenafil citrate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(impotence treatment with .alpha.-adrenergic antagonists and cGMP level elevators)

RN 139755-83-2 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 171599-83-0 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 77-92-9
CMF C6 H8 O7



L25 ANSWER 41 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:372055 HCAPLUS
DOCUMENT NUMBER: 131:23522
TITLE: **Compositions** for nasal administration
INVENTOR(S): Illum, Lisbeth; Watts, Peter James
PATENT ASSIGNEE(S): Danbiosyst UK Limited, UK
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9927905	A1	19990610	WO 1998-GB3572	19981127 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2312839	AA	19990610	CA 1998-2312839	19981127 <--
AU 9912535	A1	19990616	AU 1999-12535	19981127 <--
ZA 9810886	A	20000529	ZA 1998-10886	19981127 <--
EP 1035833	A1	20000920	EP 1998-955814	19981127 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001524509	T2	20011204	JP 2000-522892	19981127 <--
NO 2000002851	A	20000602	NO 2000-2851	20000602 <--
US 6342251	B1	20020129	US 2000-586139	20000602 <--
US 2001046519	A1	20011129	US 2001-920698	20010801 <--

PRIORITY APPLN. INFO.:			
GB 1997-25519	A	19971202	<--
GB 1998-5253	A	19980313	<--
WO 1998-GB3572	W	19981127	<--
US 2000-586139	A1	20000602	<--

AB A **compn.** for the nasal delivery of a drug suitable for the treatment of erectile dysfunction to a mammal is adapted to provide an initial rise in plasma level followed by a sustained plasma level of the drug. Examples given were apomorphine in a pectin based formulation and a Pluronic F127 formulation.

IT **139755-83-2**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nasal formulations for erectile dysfunction)

RN 139755-83-2 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 42 OF 42 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1996:458027 HCAPLUS
DOCUMENT NUMBER: 125:105133
TITLE: Bicyclic heterocyclic compounds for the treatment of impotence

INVENTOR(S): Campbell, Simon Fraser
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Research and Development Company, N.V./s.A.; Pfizer Inc.; Campbell, Simon, Fraser
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9616657	A1	19960606	WO 1995-EP4065	19951016 <--
W: CA, JP, MX, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2203389	AA	19960606	CA 1995-2203389	19951016 <--
EP 793498	A1	19970910	EP 1995-935453	19951016 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 09512835	T2	19971222	JP 1995-518108	19951016 <--
JP 2001048787	A2	20010220	JP 2000-133197	19951016 <--
US 6100270	A	20000808	US 1997-836671	19970522 <--

PRIORITY APPLN. INFO.: GB 1994-23911 A 19941126 <--
JP 1996-518108 A3 19951016 <--
WO 1995-EP4065 W 19951016 <--

OTHER SOURCE(S): MARPAT 125:105133

AB 5-Arylpyrazolo[4,3-d]pyrimidin-7-ones, 6-arylpyrazolo[3,4-d]pyrimidin-4-ones, 2-arylquinazolin-4-ones, 2-arylpurin-6-ones and 2-arylpyrido[3,2-d]pyrimidin-4-ones, or a pharmaceutically acceptable salt thereof, or a pharmaceutical **compn**. contg. either entity, are used for the curative or prophylactic treatment of erectile dysfunction in males.

IT **148871-66-3 148871-67-4 148871-68-5**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bicyclic heterocyclic compds. for the treatment of impotence)

RN 148871-66-3 HCAPLUS
CN Benzenesulfonamide, 3-(1-ethyl-4,7-dihydro-3-methyl-7-oxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-hexyl-4-propoxy- (9CI) (CA INDEX NAME)



RN 148871-67-4 HCAPLUS
CN Benzenesulfonamide, N-(cyclohexylmethyl)-3-(1-ethyl-4,7-dihydro-3-methyl-7-oxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-methyl-4-propoxy- (9CI) (CA INDEX NAME)



RN 148871-68-5 HCAPLUS
CN Benzenesulfonamide, N,N-diethyl-3-(1-ethyl-4,7-dihydro-3-methyl-7-oxo-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxy- (9CI) (CA INDEX NAME)



=> d ibib abs hitstr 123 1-10

L23 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:310983 HCAPLUS
DOCUMENT NUMBER: 136:379398
TITLE: Experience with sildenafil in diabetes
AUTHOR(S): Fedele, D.; Lamonica, M.; Bax, G.
CORPORATE SOURCE: Dipartimento di Scienze Mediche e Chirurgiche, Universita di Padova, Padua, I-35137, Italy
SOURCE: Diabetes, Nutrition & Metabolism (2002), 15(1), 49-52
CODEN: DNMEEW; ISSN: 0394-3402
PUBLISHER: Editrice Kurtis s.r.l.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. The high frequency of erectile dysfunction (ED) in Italy may be explained on one hand by the high incidence of such complications as **neuropathy** and vasculopathy, and by the high frequency of hypertension and related drugs as well as the advanced age diabetic subjects. The appearance of ED in diabetic subjects imposes a therapeutic regimen, which first consists of administering sildenafil, a drug that is easy to take and also highly tolerated, partly because of its minor side effects. It makes more c-GMP available by inhibiting PDE-5, and sexual performance is generally satisfactory. The best response to sildenafil is seen in subjects with psychogenic ED in which the incidence is 80%, while it is very low in diabetic subjects. The frequency of adverse-effects in diabetic and non-diabetic subjects is similar, the most common being flushing, headache, sinus congestion or discharge.

IT **139755-83-2**, Sildenafil
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sildenafil for erectile dysfunction in diabetes mellitus patients)
RN 139755-83-2 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:72805 HCAPLUS
DOCUMENT NUMBER: 136:139829
TITLE: Compositions comprising sibutramine metabolites in combination with phosphodiesterase inhibitors
INVENTOR(S): Jerussi, Thomas P.; Senanayake, Chrisantha H.; Fang, Qun K.
PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 24 pp., Cont.-in-part of U.S. Ser. No. 662,135.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002010198	A1	20020124	US 2001-770663	20010129
US 6331571	B1	20011218	US 1999-372158	19990811
US 6339106	B1	20020115	US 2000-662135	20000914
WO 2002060424	A2	20020808	WO 2002-US2040	20020123

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
US 1999-372158 A2 19990811
US 2000-662135 A2 20000914
US 1998-97665P P 19980824
US 1998-99306P P 19980902
US 2001-770663 A 20010129

AB Methods are disclosed for the treatment and prevention of disorders and conditions such as, but are not limited to: eating disorders; wt. gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as **neuropathic** pain, diabetic **neuropathy**, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence. Pharmaceutical compns. and dosage forms are also disclosed which comprise a racemic or optically pure sibutramine metabolite and an optional drug. Sibutramine free base was prepd. by the reaction of chlorbenzylnitrile dibromopropane in the presence of NaH in DMSO, followed by the treatment of the resulting 1-(4-chlorophenyl)cyclobutanecarbonitrile with isobutylmagnesium bromide and finally treatment with HCHO. The fee base was resolved into the (R) and (S) isomers and converted into their metabolites. Hard gelatin capsules contained racemic or optically pure sibutramine metabolite 5.0, microcryst. cellulose 90.0, pregelatinized starch 100.3, croscarmellose sodium 7.0, and Mg stearate 0.2 mg.

IT **139755-83-2**, Sildenafil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. comprising sibutramine metabolites in combination with phosphodiesterase inhibitor)

RN 139755-83-2 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



IT **139755-82-1**, Desmethylsildenafil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(desmethylsildenafil; compns. comprising sibutramine metabolites in combination with phosphodiesterase inhibitor)
RN 139755-82-1 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



L23 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:51989 HCAPLUS
DOCUMENT NUMBER: 136:96083
TITLE: Methods of using and compositions comprising (+)-sibutramine optionally in combination with other pharmacologically active compounds
INVENTOR(S): Young, James W.; Jerussi, Thomas P.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U. S. Ser. No. 442,263.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002006964	A1	20020117	US 2001-770393	20010129
WO 2002060427	A2	20020808	WO 2002-US2038	20020123

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1995-442263 A2 19950516
US 2001-770393 A 20010129

AB This invention encompasses methods for the treatment and prevention of disorders that include, but are not limited to, eating disorders; wt. gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as **neuropathic** pain, diabetic **neuropathy**, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence. The invention further encompasses pharmaceutical compns. and dosage forms which comprise optically pure (+)-sibutramine, optionally in combination with a phosphodiesterase inhibitor or a lipase inhibitor.

IT **139755-82-1**, Desmethylsildenafil
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(desmethylsildenafil; therapeutic compns. comprising (+)-sibutramine and optionally in combination with other pharmacol. active compds.)

RN 139755-82-1 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



IT **139755-83-2**, Sildenafil
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic compns. comprising (+)-sibutramine and optionally in combination with other pharmacol. active compds.)

RN 139755-83-2 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



L23 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:51988 HCAPLUS
DOCUMENT NUMBER: 136:107551
TITLE: Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds
INVENTOR(S): Young, James W.; Jerussi, Thomas P.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S. Ser. No. 721,669.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002006963	A1	20020117	US 2001-770665	20010129
WO 2002060428	A2	20020808	WO 2002-US2039	20020123

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 1992-903040	B1	19920623
US 1995-461608	B1	19950605
US 2000-721669	A2	20001127
US 2001-770665	A	20010129

AB This invention encompasses methods for the treatment and prevention of disorders that include, but are not limited to, eating disorders; wt. gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as **neuropathic** pain, diabetic **neuropathy**, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence. The invention further encompasses pharmaceutical compns. and dosage forms which comprise optically pure (-) sibutramine, optionally in combination with a phosphodiesterase inhibitor or a lipase inhibitor. A soln. of 21.7 g L-dibenzyltartaric acid ("L-DBTA") in Et acetate was added to a soln. of 12.3 g racemic sibutramine in Et acetate and the reaction mixt. was heated to reflux and cooled to room temp. The white ppt. was collected and the solid was then suspended in Et acetate and heated at reflux for 30 min. The solid was collected and further crystd. in iso-Pr alc. to give 11.3 g of (-)-sibutramine L-DBTA (yield 76%). Free base was obtained by treatment of (-)-sibutramine L-DBTA with satd. aq. NaHCO3 and extd. with chloroform. A pharmacol. study was conducted to det. the relative potency, comparative efficacy, binding affinity, and toxicity of the enantiomers and racemic mixt. of sibutramine. A capsule contained (-) sibutramine 10.0, lactose 70.0, corn starch 19.5, and magnesium stearate 0.05 mg.

IT **139755-82-1**, Desmethylsildenafil **139755-83-2**, Sildenafil

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method of using and compns. comprising (-) sibutramine optionally in combination with other pharmacol. active compds.)

RN 139755-82-1 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 139755-83-2 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



L23 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:31259 HCAPLUS
DOCUMENT NUMBER: 136:64173
TITLE: Method using sildenafil or other cGMP phosphodiesterase 5 inhibitor for treating peripheral vascular diseases, peripheral **neuropathies**, and autonomic **neuropathies**
INVENTOR(S): Wood, Ralph E.
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002118	A1	20020110	WO 2001-US41202	20010629

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001079275 A5 20020114 AU 2001-79275 20010629
PRIORITY APPLN. INFO.: US 2000-215065P P 20000630
US 2000-219029P P 20000718
WO 2001-US41202 W 20010629

AB A method is provided for treating a patient suffering from peripheral vascular disease, peripheral **neuropathies**, or autonomic **neuropathies** by administering a cGMP PDE5 inhibitor such as sildenafil. The method is particularly applicable to patients suffering from diabetic foot ulcers, Raynaud's Phenomenon, CREST Syndrome, erythromatosis, rheumatoid diseases, diabetic retinopathies and onychomycosis. According to the invention, a cGMP PDE5 inhibitor may be administered as a prophylactic to patients predisposed to develop a peripheral vascular disease, peripheral **neuropathy**, or autonomic **neuropathy**.

IT **139755-83-2**, Sildenafil
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sildenafil or other cGMP phosphodiesterase 5 inhibitor for treatment of peripheral vascular diseases and peripheral and autonomic **neuropathies**)

RN 139755-83-2 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:338762 HCAPLUS
DOCUMENT NUMBER: 134:362292
TITLE: Methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile
INVENTOR(S): Farr, Spencer
PATENT ASSIGNEE(S): Phase-1 Molecular Toxicology, USA
SOURCE: PCT Int. Appl., 222 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032928	A2	20010510	WO 2000-US30474	20001103
WO 2001032928	A3	20020725		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-165398P P 19991105
US 2000-196571P P 20000411

AB The invention discloses methods, gene databases, gene arrays, protein arrays, and devices that may be used to det. the hypersensitivity of individuals to a given agent, such as drug or other chem., in order to prevent toxic side effects. In one embodiment, methods of identifying hypersensitivity in a subject by obtaining a gene expression profile of multiple genes assocd. with hypersensitivity of the subject suspected to be hypersensitive, and identifying in the gene expression profile of the subject a pattern of gene expression of the genes assocd. with hypersensitivity are disclosed. The gene expression profile of the subject may be compared with the gene expression profile of a normal individual and a hypersensitive individual. The gene expression profile of the subject that is obtained may comprise a profile of levels of mRNA or cDNA. The gene expression profile may be obtained by using an array of nucleic acid probes for the plurality of genes assocd. with hypersensitivity. The expression of the genes predetd. to be assocd. with hypersensitivity is directly related to prevention or repair of toxic damage at the tissue, organ or system level. Gene databases arrays and app. useful for identifying hypersensitivity in a subject are also disclosed.

IT **171599-83-0**, Sildenafil citrate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

RN 171599-83-0 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 77-92-9
CMF C6 H8 O7



L23 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:283791 HCAPLUS
DOCUMENT NUMBER: 134:290420
TITLE: Sildenafil and other pyrazolopyrimidine derivatives for treatment of **neuropathies**
INVENTOR(S): Lareida, Jurg
PATENT ASSIGNEE(S): Switz.
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001026659	A1	20010419	WO 2000-CH409	20000727
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1220672	A1	20020710	EP 2000-943518	20000727
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

PRIORITY APPLN. INFO.: CH 1999-1862 A 19991012
WO 2000-CH409 W 20000727
OTHER SOURCE(S): MARPAT 134:290420
GI



I

AB Compds. I (R1 = C1-6 alkyl, optionally halo-substituted; R2 = H, C1-4 alkyl, optionally halo-substituted or replaced by halo; R3 = C2-4 alkyl, optionally halo-substituted; R4 = SO2NR5R6, CO2R7 etc.; R5, R6 = H, C1-4 alkyl, or, together with the N atom to which they are attached, form pyrrolidino, piperidino, morpholino, etc.; R7 = H, C1-4 alkyl, optionally fluoro-substituted), or the pharmaceutically acceptable salts thereof, are useful for the chemotherapeutic treatment of **neuropathies**.

IT **139755-83-2**, Sildenafil
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sildenafil and other pyrazolopyrimidine derivs. for **neuropathy** treatment)

RN 139755-83-2 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:255742 HCAPLUS
DOCUMENT NUMBER: 135:190353
TITLE: Sildenafil: Evidence and shadows
AUTHOR(S): Pavone-Macaluso, M.; Lamartina, M.; Pavone, C.; Vella, M.; Melloni, D.
CORPORATE SOURCE: Institute of Urology, University of Palermo (I), Palermo, Italy
SOURCE: International Congress on Therapy in Andrology: The Human Testis: Its Role in Reproduction and Sexuality, 4th, Pisa, Italy, Oct. 14-16, 1999 (1999), 113-116. Editor(s): Menchini-Fabris, G. F. Monduzzi Editore S.p.A.: Bologna, Italy.
CODEN: 69BDFM
DOCUMENT TYPE: Conference
LANGUAGE: English

AB Sildenafil citrate (S.) has been com. available in Italy for almost a year. Our present experience shows that is effective in most cases, including urol. conditions such as erectile dysfunction (ED) assocd. with **neuropathic** bladder and ED following radiotherapy and radical surgery for prostate cancer. Risks and side effects are minimal, provided the contraindications are known and taken in considerations. Few problems still remain to be solved. Lack of satisfaction and malpractice litigations can be kept to a min. if the indications are properly selected.

IT **171599-83-0**, Sildenafil citrate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sildenafil use in humans)
RN 171599-83-0 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 77-92-9
CMF C6 H8 O7



L23 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:114953 HCAPLUS
DOCUMENT NUMBER: 134:157562
TITLE: Methods and pharmaceutical compositions for increasing optic nerve, choroidal and retinal blood flow by cyclic-GMP analogs, cyclic-GMP phosphodiesterase inhibitors, or guanylate cyclase activators.
INVENTOR(S): Sponsel, William E.
PATENT ASSIGNEE(S): Board of Regents, the University of Texas System, USA
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2001010406 A2 20010215 WO 2000-US21929 20000810
WO 2001010406 A3 20020808
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1246605 A2 20021009 EP 2000-952721 20000810
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL
PRIORITY APPLN. INFO.: US 1999-148150P P 19990810
WO 2000-US21929 W 20000810

AB A method is provided for improving visual function and maximizing the health of the optic nerve and retina by increasing blood flow velocity therein through the application of an effective amt. of a formulation of an agent that is a cyclic-GMP analog, a cyclic-GMP phosphodiesterase inhibitor, or a guanylate cyclase activator. Compds. of the invention include e.g. sildenafil citrate (Viagra).

IT **139755-83-2**, Sildenafil **171599-83-0**, Sildenafil citrate
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclic-GMP analog, cyclic-GMP phosphodiesterase inhibitor, or guanylate cyclase activator for increasing optic nerve, choroidal and retinal blood flow.)

RN 139755-83-2 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 171599-83-0 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139755-83-2
CMF C22 H30 N6 O4 S



CM 2

CRN 77-92-9
CMF C6 H8 O7



L23 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:98405 HCAPLUS
DOCUMENT NUMBER: 134:141774
TITLE: Methods, pharmaceutical compositions comprising cyclic guanosine 3',5'-monophosphate phosphodiesterase type 5 inhibitors for prophylactic and treatment of diseases and conditions of the eye
INVENTOR(S): Laties, Alan Malev
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 9 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1074258	A2	20010207	EP 2000-306235	20000721
EP 1074258	A3	20010418		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001048788	A2	20010220	JP 2000-222162	20000724
US 2002119974	A1	20020829	US 2002-126375	20020419

PRIORITY APPLN. INFO.: US 1999-146095P P 19990728
US 2000-607562 B1 20000629
OTHER SOURCE(S): MARPAT 134:141774
GI



I

AB The invention describes methods using cyclic guanosine 3',5'-monophosphate phosphodiesterase type 5 inhibitors (I) [R1= H, C1-C3 alkyl, C3-C5 cycloalkyl, perfluoroalkyl; R2= H, (hydroxyl-substituted) C1-C6 alkyl, C3-C6 cycloalkyl, etc.; R3= C1-C6 alkyl, C3-C6 alkenyl, C3-C6 alkynyl, etc.; R4N completes pyrrolidinyl, morpholino, etc.; R5= H, C1-C4 alkyl, C1-C3 alkoxy, etc.] for prophylactic and therapeutic administration in patients with eye diseases and conditions including:central retinal artery occlusion; central retinal vein occlusion; optic **neuropathy** including, but not limited to, anterior ischemic optic **neuropathy** and glaucomatous optic **neuropathy**; and macular (dry) degeneration. Pharmaceutical compns. comprising cyclic guanosine 3',5'-monophosphate phosphodiesterase type 5 inhibitors are also disclosed.

IT **139755-81-0 139755-82-1 139755-83-2**
139755-84-3 139755-85-4 139755-86-5
139755-87-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phosphodiesterase type 5 inhibitors for prophylactic and treatment of eye diseases)

RN 139755-81-0 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-(2-propenyloxy)phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 139755-82-1 HCAPLUS

CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 139755-83-2 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 139755-84-3 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-(1-methyl)- (9CI) (CA INDEX NAME)



RN 139755-85-4 HCAPLUS
CN 1-Piperazineethanol, 4-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 139755-86-5 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 139755-87-6 HCAPLUS
CN 1-Piperazineethanol, 4-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxyphenyl]sulfonyl]- (9CI) (CA INDEX NAME)



psychotic disorder, major depressive mood disorder, bipolar disorder with psychotic features, seasonal affective. . .

=>

(FILE 'HOME' ENTERED AT 20:22:23 ON 09 MAR 2003)

FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CANCERLIT, CAPLUS, CEN, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, DRUGNL, DRUGU, EMBAL, EMBASE, ESBIOBASE, IFIPAT, IPA, JICST-EPLUS, KOSMET, LIFESCI, MEDICONF, MEDLINE, NAPRALERT, NLDB, NUTRACEUT, ...' ENTERED AT 20:22:28 ON 09 MAR 2003

L1	20424	S	TOURETT?
L2	19571	S	(NEUROPATHY OR NEUROPATHIES) (P) (DYSFUNCTION OR DISORDER)
L3	9735	DUP REM	L2 (9836 DUPLICATES REMOVED)
L4	24542	S	(NEUROPATHY OR NEUROPATHIES) (P) (CENTRAL NERVOUS SYSTEM)
L5	295	S	CENTRAL (W) NEUROPATHY
L6	97	S	L5 AND (CENTRAL (W) NERVOUS (W) SYSTEM)
L7	64	DUP REM	L6 (33 DUPLICATES REMOVED)

FILE 'USPATFULL' ENTERED AT 20:47:21 ON 09 MAR 2003

L8	2	S	NEUOPATHY/CLM,AB,TI
L9	745	S	NEUROPATHY/CLM,AB,TI
L10	325	S	L9 AND CENTRAL (W) NERVOUS (W) SYSTEM
L11	111	S	L10 AND (CENTRAL (P) NEUROPATHY)
L12	675	S	NEUROPATHY/CLM
L13	89	S	NEUROPATHY/AB AND L12
L14	26	S	NEUROPATHY/TI AND L13
L15	8	S	L14 AND (CENTRAL (W) NERVOUS (W) SYSTEM)

```
=> d his full

     FILE 'REGISTRY' ENTERED AT 10:29:25 ON 11 OCT 2002
                ACT KIM113L17/A
               ---------
L1                STR  see d que L1 for structure
L2   (       133)SEA SSS FUL L1
L3                STR  see d que L3 for structure
L4   (       182)SEA SSS FUL L3
L5           315 SEA ABB=ON  L2 OR L4  315 compds for L1 or L3
               ---------
     FILE 'HCAPLUS' ENTERED AT 10:32:05 ON 11 OCT 2002
                ACT KIM113L18/A
               ---------
L6                STR - same as L1
L7   (       133)SEA SSS FUL L6
L8                STR - same as L3
L9   (       182)SEA SSS FUL L8
L10  (       315)SEA ABB=ON  L7 OR L9
L11          504 SEA ABB=ON  L10  504 cits for L1 or L3
               ---------
L12          351 SEA ABB=ON  L11 AND (?COMP? OR ?PREP? OR ?COMB?)
L13           61 SEA ABB=ON  L11 AND ?COMPOS?  61 cits for "composition"
L14           60 SEA ABB=ON  L11 AND ?COMPOSIT?
                 D TI 1-10
L15            0 SEA ABB=ON  L14 AND LAREIDA J/AU
L16            0 SEA ABB=ON  L14 AND LAREIDA J?/AU
                 D SAVED
                 ACT KIM113/A
               ---------
L17               STR
L18  (       133)SEA SSS FUL L17
L19               STR
L20  (       182)SEA SSS FUL L19
L21  (       315)SEA ABB=ON  L18 OR L20
L22  (       504)SEA ABB=ON  L21
L23           10 SEA ABB=ON  L22 AND (?NEUROPATH? OR ?NERV?(W)?DISEAS?)
               ---------      10 cits used for neuropathies - attached per your query (2)
L24            5 SEA ABB=ON  L23 AND COMPOSIT?
L25           42 SEA ABB=ON  L13 AND PRD<20000727  42 cits when limited by
                                                   priority date - attached per
                                                   your query(1)
```

=> d que l1
L1 STR



N is left unspecified, per Claim 1, compd I

VAR G1=H/22
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M1-X6 C AT 19
ECOUNT IS M2-X4 C AT 23

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 23

STEREO ATTRIBUTES: NONE

=> d que l3
L3 STR



N is specified for "ring"; per Claim 2, compd Ia, and Claim 3, Compd 3

VAR G1=H/22
NODE ATTRIBUTES:
NSPEC IS R AT 21
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M1-X6 C AT 19
ECOUNT IS M2-X4 C AT 23

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 23

STEREO ATTRIBUTES: NONE

=> d ibib abs hitstr 1-2

L3 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:283791 HCAPLUS
DOCUMENT NUMBER: 134:290420
TITLE: Sildenafil and other pyrazolopyrimidine derivatives for treatment of neuropathies
INVENTOR(S): **Lareida, Jurg**
PATENT ASSIGNEE(S): Switz.
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001026659	A1	20010419	WO 2000-CH409	20000727
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1220672	A1	20020710	EP 2000-943518	20000727
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

PRIORITY APPLN. INFO.: CH 1999-1862 A 19991012
WO 2000-CH409 W 20000727
OTHER SOURCE(S): MARPAT 134:290420
GI



I

AB Compds. I (R1 = C1-6 alkyl, optionally halo-substituted; R2 = H, C1-4 alkyl, optionally halo-substituted or replaced by halo; R3 = C2-4 alkyl, optionally halo-substituted; R4 = SO2NR5R6, CO2R7 etc.; R5, R6 = H, C1-4 alkyl, or, together with the N atom to which they are attached, form pyrrolidino, piperidino, morpholino, etc.; R7 = H, C1-4 alkyl, optionally fluoro-substituted), or the pharmaceutically acceptable salts thereof, are useful for the chemotherapeutic treatment of neuropathies.

IT **139755-83-2**, Sildenafil
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sildenafil and other pyrazolopyrimidine derivs. for neuropathy

treatment)
RN 139755-83-2 HCAPLUS
CN Piperazine, 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:341597 HCAPLUS
DOCUMENT NUMBER: 131:97841
TITLE: Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2
AUTHOR(S): Gutzwiller, Jean-Pierre; Drewe, Jurgen; Goke, Burkhard; Schmidt, Harald; Rohrer, Beat; **Lareida, Jurg**; Beglinger, Christoph
CORPORATE SOURCE: Department of Internal Medicine, Kantonsspital, Aarau, CH-5000, Germany
SOURCE: American Journal of Physiology (1999), 276(5, Pt. 2), R1541-R1544
CODEN: AJPHAP; ISSN: 0002-9513
PUBLISHER: American Physiological Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Glucagon-like peptide-1-(7-36) amide (GLP-1) is an incretin hormone of the enteroinsular axis. Recent exptl. evidence in animals and healthy subjects suggests that GLP-1 has a role in controlling appetite and energy intake in humans. The authors have therefore examd. in a double-blind, placebo-controlled, crossover study in 12 patients with diabetes type 2 the effect of i.v. infused GLP-1 on appetite sensations and energy intake. On 2 days, either saline or GLP-1 (1.5 pmol.cntdot.kg-1.cntdot.min-1) was given throughout the expt. Visual analog scales were used to assess appetite sensations; furthermore, food and fluid intake of a test meal were recorded, and blood was sampled for anal. of plasma glucose and hormone levels. GLP-1 infusion enhanced satiety and fullness compared with placebo (P = 0.028 for fullness and P = 0.026 for hunger feelings). Energy intake was reduced by 27% by GLP-1 (P = 0.034) compared with saline. The results demonstrate a marked effect of GLP-1 on appetite by showing enhanced satiety and reduced energy intake in patients with diabetes type 2.
IT **50-99-7**, D-Glucose, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(blood; glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2)
RN 50-99-7 HCAPLUS
CN D-Glucose (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **89750-14-1**, Glucagon-like peptide I **118549-37-4**, Insulinotropin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2)
RN 89750-14-1 HCAPLUS
CN Glucagon-like peptide I (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 118549-37-4 HCAPLUS
CN Insulinotropin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **9004-10-8**, Insulin, biological studies **9007-92-5**, Glucagon, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2)
RN 9004-10-8 HCAPLUS
CN Insulin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9007-92-5 HCAPLUS
CN Glucagon (7CI, 8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT